No connection

Search Results

AAPG vs ABBV

AAPG
Ascentage Pharma Group Internat
BEARISH
Price
$22.32
Market Cap
$2.09B
Sector
Healthcare
AI Confidence
85%
ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%

Valuation

P/E Ratio
AAPG
--
ABBV
163.63
Forward P/E
AAPG
-46.43
ABBV
15.42
P/B Ratio
AAPG
79.25
ABBV
-146.66
P/S Ratio
AAPG
5.35
ABBV
6.5
EV/EBITDA
AAPG
-7.41
ABBV
15.27

Profitability

Gross Margin
AAPG
90.87%
ABBV
71.46%
Operating Margin
AAPG
-237.05%
ABBV
35.5%
Profit Margin
AAPG
-296.77%
ABBV
4.0%
ROE
AAPG
-159.65%
ABBV
137.96%
ROA
AAPG
-22.77%
ABBV
9.59%

Growth

Revenue Growth
AAPG
-71.6%
ABBV
9.1%
Earnings Growth
AAPG
--
ABBV
-88.7%

Financial Health

Debt/Equity
AAPG
2.54
ABBV
--
Current Ratio
AAPG
1.54
ABBV
0.72
Quick Ratio
AAPG
1.4
ABBV
0.47

Dividends

Dividend Yield
AAPG
--
ABBV
3.05%
Payout Ratio
AAPG
0.0%
ABBV
490.15%

AI Verdict

AAPG BEARISH

AAPG's Piotroski F-Score of 4/9 indicates weak financial health, with no Altman Z-Score available to assess bankruptcy risk. The company exhibits severe profitability issues, with a negative profit margin of -296.77% and ROE of -159.65%, alongside a 71.6% YoY revenue decline. Despite a high gross margin of 90.87%, the business is not generating sustainable earnings. The stock trades at a premium valuation (Price/Book: 79.25) with no intrinsic value or Graham Number, suggesting speculative pricing. Analysts rate it a 'strong_buy' with a target of $49.14, but this is not supported by fundamentals.

Strengths
High gross margin of 90.87% indicates strong product-level pricing power or cost control
Analyst consensus is 'strong_buy' with a significant target price upside of ~120%
Recent 1-year return of +17.7% shows some market momentum despite fundamentals
Risks
Piotroski F-Score of 4/9 signals weak financial health and deteriorating operational efficiency
Negative profit margin (-296.77%) and ROE (-159.65%) indicate severe unprofitability
71.6% YoY revenue decline reflects a shrinking business model or failed product pipeline
ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security

Compare Another Pair

AAPG vs ABBV: Head-to-Head Comparison

This page compares Ascentage Pharma Group Internat (AAPG) and AbbVie Inc. (ABBV) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile